Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization
Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.
Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.